RESULTS ROUND-UP: Abiomed, Roche, Stryker positive; Siemens must do better
This article was originally published in Clinica
Executive Summary
As expected, the US FDA has approved Abiomed’s Impella RP percutaneous heart pump under a humanitarian device exemption for right-sided heart failure. The firm also reported 34% sales growth in its third fiscal quarter, at $62.0m, as worldwide Impella revenues shot up 37% to $57.4m. Jefferies analyst Raj Denhoy said it “could prove to be its breakout quarter. Revenues of $62m handily exceeded our $52m forecast.” He added: “The performance looks sustainable as the company is calling for 20% growth in FY16.”